To evaluate the Safety and efficacy of Unani formulations in the treatment of Nephrolithiasis

Phase 2

• Conditions: Health Condition 1: N200- Calculus of kidneyHealth Condition 2: null- HasÄ?h al-Kulya (Nephrolithiasis)

• Registration Number: CTRI/2015/02/005551
• Lead Sponsor: Central Council for Research in Unani Medicine CCRUM New Delhi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 300

Inclusion Criteria

•Patients with HasÄ?h al-Kulya (nephrolithiasis) as diagnosed by X-Ray/Ultrasound KUB with calculi measuring between 3 to 6 mm with or without any of the following symptoms:

ï?§Bawl al-Dam (Haematuria)

ï?§Siqlâ?? al-Khasira (Heaviness in the Loin)

ï?§Wajaâ?? al-Khasira (Pain in the Loin)

ï?§•History of Recurrent UTI

ï?§•History of Recurrence of Renal Stone

ï?§•Urine showing Calcium Crystaluria

Exclusion Criteria

•Patients having acute condition of nephrolithiasis

•Complicated cases of nephrolithiasis requiring surgical intervention

•Patients with hydronephrosis, acute symptoms of UTI or any other renal diseases

•Patients with serum creatinine > 2mg%

•Patients on long-term medications

•Patients with cardiac, pulmonary or hepatic diseases

•Pregnancy and lactation

•Alcohol or drug abuse/ History of alcohol or drug abuse within 6 months prior to baseline

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement in signs and symptoms of HasÄ?h al-Kulya (Nephrolithiasis)Timepoint: 8 weeks

Secondary Outcome Measures

Name	Time	Method
Haematological and biochemical assessment for safety assessmentTimepoint: 8 weeks